Initiator Pharma A/S

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to treat neuropathic pain; and IP2018, a monoamine reuptake inhibitor which completed Phase IIa for the treatment of psychogenic erectile dysfunction. The company also develops IP2016, which is in preclinical development for the treatment of depression and pain; and Pudafensine and IP2018, which is in preclinical development to treat female sexual dysfunction. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.